News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,741 Results
Type
Article (13565)
Company Profile (110)
Press Release (247066)
Section
Business (87936)
Career Advice (461)
Deals (15323)
Drug Delivery (63)
Drug Development (36522)
Employer Resources (49)
FDA (6259)
Job Trends (6182)
News (150008)
Policy (14006)
Tag
Academia (435)
Alliances (23074)
Alzheimer's disease (347)
Approvals (6250)
Artificial intelligence (58)
Bankruptcy (143)
Best Places to Work (4307)
Biosimilars (39)
Biotechnology (44)
Breast cancer (40)
Cancer (286)
Career advice (405)
Cell therapy (39)
Clinical research (30327)
Collaboration (129)
Compensation (55)
COVID-19 (746)
C-suite (49)
Data (290)
Diabetes (47)
Diagnostics (1230)
Drug pricing (56)
Earnings (31447)
Employer resources (43)
Events (36638)
Executive appointments (145)
FDA (6422)
Funding (91)
Gene therapy (58)
GLP-1 (287)
Government (1264)
Healthcare (3517)
Infectious disease (763)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5808)
Job creations (2049)
Job search strategy (372)
Layoffs (166)
Legal (3409)
Lung cancer (44)
Manufacturing (85)
Medical device (1260)
Medtech (1262)
Mergers & acquisitions (9534)
Metabolic disorders (154)
Neuroscience (436)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (388)
Obesity (96)
Opinion (108)
Patents (51)
People (28405)
Pharmaceutical (64)
Phase I (7886)
Phase II (12824)
Phase III (11526)
Pipeline (134)
Podcasts (39)
Policy (43)
Postmarket research (1399)
Preclinical (3161)
Radiopharmaceuticals (116)
Rare diseases (82)
Real estate (2629)
Regulatory (9801)
Research institute (562)
Resumes & cover letters (55)
Southern California (398)
Startups (1624)
United States (3905)
Vaccines (109)
Weight loss (76)
Date
Today (63)
Last 7 days (335)
Last 30 days (1077)
Last 365 days (12668)
2024 (11101)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (39)
Asia (19753)
Australia (2552)
California (907)
Canada (561)
China (100)
Connecticut (37)
Europe (38697)
Florida (130)
Illinois (102)
Indiana (81)
Kansas (51)
Maryland (146)
Massachusetts (802)
Minnesota (50)
New Jersey (384)
New York (251)
North Carolina (269)
Northern California (388)
Pennsylvania (265)
South America (498)
Southern California (398)
Texas (122)
Virginia (37)
Washington State (66)
260,741 Results for "rivus pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Rivus Targets Weight-Loss Drug Market With Mid-Stage Win in Obesity-Related Heart Failure
Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.
August 14, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial Rationale and Design in European Journal of Heart Failure
Rivus Pharmaceuticals today announced publication of the rationale and design of the company’s Phase 2a HuMAIN trial in the European Journal of Heart Failure.
June 26, 2024
·
6 min read
Business
Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments
Rivus Pharmaceuticals Inc. today announced key clinical and corporate updates.
November 15, 2023
·
7 min read
Drug Development
Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6
Rivus Pharmaceuticals Inc. today announced the completion of enrollment in its Phase 2a HuMAIN trial of HU6, an investigational controlled metabolic accelerator (CMA), in patients with the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
January 5, 2024
·
5 min read
Business
Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO
Rivus Pharmaceuticals Inc. today announced the appointment of Jayson Dallas, M.D., executive chairman for Rivus Pharmaceuticals, as Chief Executive Officer.
June 29, 2023
·
4 min read
Weight Loss
Beyond GLP-1s: The Next Obesity Treatments
Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.
July 8, 2024
·
6 min read
·
Heather McKenzie
Drug Development
Beyond GLP-1s: The Next Obesity Treatments
Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.
June 28, 2024
·
6 min read
·
Heather McKenzie
Drug Development
Phase 2a Study of HU6, Rivus Pharmaceuticals’ Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High Body Mass Index and Nonalcoholic Fatty Liver Disease
Rivus Pharmaceuticals Inc. today announced publication in The Lancet Gastroenterology & Hepatology of the results of a Phase 2a metabolic study of HU6, an investigational first-in-class controlled metabolic accelerator (CMA), in patients with nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD), and a high body mass index (BMI).
October 5, 2023
·
7 min read
BioCapital
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Rivus Pharmaceuticals Inc. today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital.
September 22, 2022
·
4 min read
Business
Rivus Scores $132M to Advance Obesity Drug, Cardio-Metabolic Pipeline
Rivus raised $132 million in a Series B financing round that will be used in developing HU6, a new drug class designed to treat cardio-metabolic disease by addressing obesity.
September 22, 2022
·
3 min read
·
Alex Keown
1 of 26,075
Next